Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2006 Oct;55(10):1524-5.
doi: 10.1136/gut.2006.099143.

Anti-TNF-alpha therapy for orofacial granulomatosis: proceed with caution

D R Gaya, S Aitken, J Fennell, J Satsangi, A G Shand
Case Reports

Anti-TNF-alpha therapy for orofacial granulomatosis: proceed with caution

D R Gaya et al. Gut. 2006 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

References

    1. Weisenfeld D, Ferguson M M, Mitchell D N.et al Oro‐facial granulomatosis—a clinical and pathological analysis. Q J Med 198554101–113. - PubMed
    1. Hegarty A, Hodgson T, Porter S. Thalidomide for the treatment of recalcitrant oral Crohn's diease and orofacial granulomatosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 200395576–585. - PubMed
    1. Mahadevan U, Sandborn W J. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 2001738–42. - PubMed
    1. Youdim A, Vasiliauskas E A, Targan S R.et al A pilot study of adalimumab in infliximab‐allergic patients. Inflamm Bowel Dis 200410333–338. - PubMed
    1. Papadakis K A, Shayne O A, Vasiliamskas E A.et al Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 200510075–79. - PubMed

MeSH terms